IFNB1 and cancer: This observation provides the rationale for using low-dose IFN-β in combination with chemotherapy in immune-competent murine models, to specifically target and prevent de-differentiation, effectively eliminating an escape mechanism that cancer cells can use when confronted with cytotoxic therapy.